Pneoo Tx

Chronic obstructive pulmonary disease (COPD) stands as the world's third leading cause of death, lacking a cure to date. Our pioneering efforts focus on developing a small molecule targeting a novel protein involved in the restoration of ciliated cells within COPD airways. Strengthened by years of a joint investment in the science, from both LUMC and Janssen Pharmaceutical Research & Discovery, we have developed a (multi) patented approach. With an exclusive license to this patent estate, Pneoo Tx will safeguard this intellectual property. In vitro experiments using (COPD) patient-derived cells have demonstrated the transformative potential of our strategy. Inhibiting the target protein triggers the formation of ciliated cells, indicative of the restoration healthy lung tissue. Having unraveled the crystal structure and mode of action of the target protein, we have initiated a directed screen for small molecules inhibiting its function. Guided by a seasoned team, including a specialist MD and industry veterans with extensive drug discovery and development experience, Pneoo Tx is well-equipped to drive our vision forward.

Join us in addressing the root cause of the disease so that we can offer a first-in-class, disease- modifying therapy for patients suffering from COPD.